Literature DB >> 21828201

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.

A Scott Nielsen, Augusto Miravalle, Annette Langer-Gould, Joanna Cooper, Keith R Edwards, R Philip Kinkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21828201     DOI： 10.1177/1352458511418631

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  9 in total

1.  Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.

Authors:  Susanna Brauner; Ann Eriksson-Dufva; Max Albert Hietala; Thomas Frisell; Rayomand Press; Fredrik Piehl
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

Review 2.  Humoral-targeted immunotherapies in multiple sclerosis.

Authors:  Sabeen Lulu; Emmanuelle Waubant
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 3.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 4.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 5.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

6.  Low-dose rituximab should be used for treating MS in resource-limited settings: No.

Authors:  Farrah J Mateen
Journal:  Mult Scler       Date:  2022-04-18       Impact factor: 5.855

7.  Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.

Authors:  Fredrik Piehl; Thomas Mathew
Journal:  Mult Scler       Date:  2022-04-18       Impact factor: 5.855

8.  Rituximab in paediatric onset multiple sclerosis: a case series.

Authors:  Jonatan Salzer; Jan Lycke; Ronny Wickström; Hans Naver; Fredrik Piehl; Anders Svenningsson
Journal:  J Neurol       Date:  2015-11-24       Impact factor: 6.682

Review 9.  Rituximab for the treatment of multiple sclerosis: a review.

Authors:  Clara Grazia Chisari; Eleonora Sgarlata; Sebastiano Arena; Simona Toscano; Maria Luca; Francesco Patti
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 6.682
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.